Patents Assigned to The Institut National de la Sante et de la Recherche Medicale (INSERM)
  • Method for inducing extended self-renewal of functionally differentiated somatic cells
    Patent number: 9175265
    Abstract: Mouse or human hematopoietic cells are transduced in vitro with one or more vectors encoding c-Myc and Klf4 genes, to overexpress both c-Myc and Klf4. The transduced cells produce self-renewing populations of macrophages, monocytes, monocyte-derived macrophages, B lymphocytes or erythroid cells. The self-renewing cell populations may include a pharmaceutical composition.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: November 3, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite de la Mediterranee (Aix-Marseille II)
    Inventor: Michael Sieweke
  • FLT3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OR THE PREVENTION OF PAIN DISORDERS
    Publication number: 20150307887
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Application
    Filed: July 8, 2015
    Publication date: October 29, 2015
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER 1, UNIVERSITE MONTPELLIER 2 SCEINCES ET TECHNIQUES
    Inventor: Jean VALMIER
  • Methods and pharmaceutical compositions for inhibiting influenza viruses replication
    Patent number: 9168236
    Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?-monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: October 27, 2015
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Université Claude Bernard - Lyon 1
    Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
  • Method for Diagnosing a Hemoglobin-Related Disorder
    Publication number: 20150293126
    Abstract: The invention relates to a method for diagnosing, staging and/or monitoring a hemoglobin-related disorder such as ?-thalassemia or a treatment against said hemoglobin-related disorder in a subject in need thereof based on the detection and/or quantification the presence of free ?-Hb pool in a biological sample obtained from said subject.
    Type: Application
    Filed: June 24, 2015
    Publication date: October 15, 2015
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris-Sud, Assistance Publique - Hopitaux de Paris, Universite Paris Est Creteil Val de Marne
    Inventors: Veronique Baudin-Creuza, Corinne Vasseur, Frederic Galacteros
  • METHODS FOR CANCER MANAGEMENT TARGETING CO-029
    Publication number: 20150291691
    Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.
    Type: Application
    Filed: April 21, 2015
    Publication date: October 15, 2015
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE DE PARIS XI PARIS SUD
    Inventors: Eric RUBINSTEIN, Céline GRECO, François LE NAOUR, Claude BOUCHEIX
  • Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof
    Publication number: 20150291669
    Abstract: Recombinant Mycobacteria (rMyc) which contain sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein are provided, as are methods of making and using the rMyc and the fusion protein. The fusion protein includes an amino terminal mycobacterial antigen Ag85B leader peptide and transcription of the fusion protein is driven by an Ag85B promoter sequence. The recombinant fusion protein is produced in abundance by the rMyc, is post-translationally methylated, and is highly antigenic.
    Type: Application
    Filed: April 16, 2012
    Publication date: October 15, 2015
    Applicants: Aeras Global TB Vaccine Foundation, Institut National De La Sante Et De La Recherche Medicale (INSERM)
    Inventors: John Fulkerson, Michael Brennan, Kamalakannan Velmurugan, Camille Locht
  • Expression vector for cholesterol 24-hydrolase in therapy of Huntington's disease
    Patent number: 9132173
    Abstract: The present invention relates to a vector for use in the treatment of Huntington's disease, which vector comprises a cholesterol 24-hydroxylase encoding nucleic acid.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: September 15, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes, Universite Evry Val d'essone, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Jocelyne Caboche, Patrick Aubourg, Nathalie Cartier, Sandrine Betuing
  • LKB1 AS PREDICTIVE MARKER OF EVEROLIMUS EFFICACY IN BREAST CANCER
    Publication number: 20150250770
    Abstract: Method for identifying a breast cancer likely to respond to treatment with everolimus comprising the following steps: Measuring the level of expression of the LKB 1 gene in a breast tumour sample previously taken from a breast cancer patient, Classifying the breast cancer as likely to respond to treatment with everolimus if the LKB1 gene is under-expressed in said breast tumour sample.
    Type: Application
    Filed: July 1, 2013
    Publication date: September 10, 2015
    Applicants: CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Isabelle Treilleux, Thomas Bachelot, Muriel Le Romancer-Cherifi
  • Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
    Patent number: 9125937
    Abstract: The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4)alkyl group or forms together with the group R1—Ar a ring fused with the Ar group, A represents a group of formula (?) or (?): R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or a group of formula (?): —Y—Z—W—R11??(?) wherein R11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO2 group, a —NR5R6 group, a —N+R5R6R7X? group, or a —OSO2R12 group, and their addition salts with pharmaceutically acceptable acids.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: September 8, 2015
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE D'AUVERGNE CLERMONT 1, LABORATORIES CYCLOPHARMA
    Inventors: Jean-Michel Chezal, Frederic Dolle, Jean-Claude Madelmont, Aurelie Maisonial, Elisabeth Miot-Noirault, Nicole Moins, Janine Papon, Bertrand Kuhnast, Bertrand Tavitian, Raphael Boisgard
  • Anti-human HER3 antibodies and uses thereof
    Patent number: 9127065
    Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: September 8, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre Val d'Aurelle—Paul Lamarque, Universite de Montpellier 1
    Inventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek
  • PAR2 agonists for use in the treatment or prevention of influenza virus type A infections
    Patent number: 9125861
    Abstract: Methods and compositions (such as pharmaceutical compositions) for treating influenza virus type A infections in human subjects include PAR2 agonists being administered to the subject. The PAR2 agonists include small organic molecules, antibodies, and aptamers. In addition, the PAR2 agonist may be a PAR2 activating peptide. Exemplary PAR2 activating peptides include SLIGRL (SEQ ID NO: 1) and SLIGKV (SEQ ID NO: 2).
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: September 8, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut National de la Recherche Agronomique (INRA)
    Inventors: Nathalie Vergnolle, Beatrice Riteau
  • FKBP52-Tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
    Patent number: 9128104
    Abstract: The invention belongs to the fields of diagnostic, prognostic, and monitoring assays of neurological disorders involving Tau dysfunction. A direct interaction between proteins FKBP52 and Tau is reported. Herein are described methods for testing a subject thought to have or be predisposed to having a neurological disorder involving Tau dysfunction; and also for preventing or treating a neurological disorder involving Tau dysfunction in a subject in need thereof.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: September 8, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Etienne Baulieu, Beatrice Chambraud
  • Methods for selecting competent oocytes and competent embryos with high potential for pregnancy outcome
    Patent number: 9121066
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.
    Type: Grant
    Filed: November 24, 2011
    Date of Patent: September 1, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Montpellier 1, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir Hamamah, Said Assou
  • Antagonists of GRASP55 for use as a medicament
    Patent number: 9107936
    Abstract: The present invention concerns antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55), for use as a medicament, in particular for use in the treatment of cell adhesion molecules implicated diseases, notably, MCAM or JAMs implicated diseases. According to some embodiments, said antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55) may be used in the treatment of cancer, metastases, and inflammatory diseases. The present invention further provides methods for screening for compounds liable of treating or preventing such diseases.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: August 18, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de la Mediterranee Aix-Marseille II
    Inventors: Michel Aurrand-Lions, Ana Zarubica
  • Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma
    Patent number: 9107893
    Abstract: The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: August 18, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), American University of Beirut
    Inventors: Hugues De The, Ali Bazarbachi, Olivier Hermine
  • FLT3 receptor antagonists for the treatment or the prevention of pain disorders
    Patent number: 9109227
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: August 18, 2015
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER 1, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES
    Inventor: Jean Valmier
  • METHODS FOR PREDICTING THE OUTCOME OF A CANCER IN A PATIENT BY ANALYSING GENE EXPRESSION
    Publication number: 20150225799
    Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.
    Type: Application
    Filed: April 24, 2015
    Publication date: August 13, 2015
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Jerome Galon, Franck Pages, Bernhard MLECNIK, Herve FRIDMAN
  • METHOD FOR ASSESSING A SUBJECT'S RISK OF HAVING A CARDIOVASCULAR DISEASE
    Publication number: 20150226749
    Abstract: The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from said subject wherein the level of EF1 is negatively correlated with the risk of said subject of having cardiovascular disease.
    Type: Application
    Filed: April 23, 2015
    Publication date: August 13, 2015
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Laurent MARTINEZ, Bertrand PERRET, Annelise GENOUX
  • NUCLEIC ACIDS TARGETING TCTP FOR USE IN THE TREATMENT OF CHEMO-OR HORMONE- RESISTANT CANCERS
    Publication number: 20150216891
    Abstract: The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.
    Type: Application
    Filed: April 16, 2015
    Publication date: August 6, 2015
    Applicants: Institut National De La Sante Et De La Recherche Medicale (Inserm), UNIVERSITE DE LA MEDITARRANEE AIX-MARSEILLE II
    Inventors: Palma ROCCHI, Virginie BAYLOT, Julie ACUNZO, Claudia ANDRIEU, Maria KATSOGIANNOU
  • Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
    Patent number: 9096868
    Abstract: This invention provides a new approach to the design of a virus with a defective replication cycle, which can be rescued by wild type virus co-infection, and which expresses foreign antigenic epitopes that contribute to the elimination of virus infected cells and then to viral clearance. The vector of the invention, by expression of epitopes derived from common pathogens, by-passes existing tolerance of virus specific T cell responses. The vector will only replicate in virus infected cells.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: August 4, 2015
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Qiang Deng, Marie-Louise Michel